A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal ...

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...

Donanemab can slow the progression of Alzheimer’s disease.But what is the drug and how does it work? Here your questions on ...

There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for ...

Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease ...

Donanemab became the second Alzheimer's drug that targets causative deposited plaque in the brain to win the coverage after ...

The drug Donanemab has been found to slow the progression of Alzheimer’s disease. Despite this is has been rejected for widespread use in the health service in England after the health spending ...

Donanemab was evaluated in a main study (Phase III Study TRAILBLAZER-ALZ 2) involving 1,736 patients with early Alzheimer’s disease who had mild cognitive impairment, mild dementia and evidence ...

The association said new treatments have become available that slow the progression of Alzheimer’s for those in the early ...

Donanemab, also known as Kisunla, has recently been licensed as a treatment for early-stage Alzheimer’s disease in the UK. However, donanemab has not been recommended for use in the NHS. Here's what ...

Donanemab can slow the progression of Alzheimer’s disease. But what is the drug and how does it work? Here your questions on the latest development in Alzheimer’s research are answered.